Advanced stage IV colorectal cancer-01

The patient is a 45-year-old male who was diagnosed with advanced stage IV colorectal cancer in January 2023. Initially, doctors recommended a full course of chemoradiotherapy. However, due to severe neurotoxicity reactions, including paresthesia and limb weakness following chemotherapy, the patient decided to discontinue further chemoradiotherapy.

Fortunately, the patient met the recruitment criteria for a clinical trial of autologous tumor-infiltrating lymphocyte (TIL) therapy and proactively chose to participate in the trial. In early April 2023, the patient received a TIL cell infusion and subsequently underwent PD-1 monoclonal antibody immunotherapy according to the trial protocol over the next two months.

Post-treatment, the patient reported significant improvement in gastrointestinal symptoms and a good recovery of bowel function. The first full-body CT scan after the infusion showed a reduction in tumor burden, particularly in the liver and peritoneal lesions. As treatment continued, the patient's physical fitness and quality of life gradually improved.

By the third month of treatment, follow-up scans indicated continued tumor shrinkage. A whole-body PET-CT scan revealed significantly reduced metabolic activity in metastatic lesions, with some lesions completely disappearing. As of now, monthly follow-ups show the tumor remains stable with no new lesions or signs of recurrence.